Aralez Pharmaceuticals Inc. (T:ARZ)
Business Focus: N/A
Aug 10, 2018 08:48 am ET
IIROC Trading Halt - ARZ
TORONTO, Aug. 10, 2018 /CNW/ - The following issues have been halted by IIROC:
Aug 10, 2018 06:00 am ET
Aralez Pharmaceuticals To Enter Into Purchase Agreements To Sell Substantially All Assets
Transactions to be valued at an aggregate of U.S.$250 million
Aug 10, 2018 06:00 am ET
Aralez Pharmaceuticals To Enter Into Purchase Agreements To Sell Substantially All Assets
Transactions to be valued at an aggregate of U.S.$250 million
Jun 29, 2018 06:10 pm ET
Aralez Announces Voting Results From 2018 Annual Meeting Of Shareholders
MISSISSAUGA, Ontario, June 29, 2018 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced the results of the matters voted upon at the Company's 2018 annual meeting (the "Meeting") of the shareholders of the Company (the "Shareholders") held earlier today, which included the election of directors, as described below.
Jun 29, 2018 06:10 pm ET
Aralez Announces Voting Results From 2018 Annual Meeting Of Shareholders
MISSISSAUGA, Ontario, June 29, 2018 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced the results of the matters voted upon at the Company's 2018 annual meeting (the "Meeting") of the shareholders of the Company (the "Shareholders") held earlier today, which included the election of directors, as described below.
Jun 29, 2018 06:10 pm ET
Aralez Enters Into Amendment To Second Amended And Restated Facility Agreement
MISSISSAUGA, Ontario, June 29, 2018 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced that, in connection with its review of strategic alternatives, it entered into an Amendment (the "Amendment") to that certain Second Amended and Restated Facility Agreement, dated as of December 7, 2015, as amended on October 3, 2016 (the "Facility Agreement"), by and between the Company and Deerfield Partners, L.P. ("Deerfield") and certain affiliates of each party.
Jun 29, 2018 06:10 pm ET
Aralez Enters Into Amendment To Second Amended And Restated Facility Agreement
MISSISSAUGA, Ontario, June 29, 2018 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced that, in connection with its review of strategic alternatives, it entered into an Amendment (the "Amendment") to that certain Second Amended and Restated Facility Agreement, dated as of December 7, 2015, as amended on October 3, 2016 (the "Facility Agreement"), by and between the Company and Deerfield Partners, L.P. ("Deerfield") and certain affiliates of each party.
May 08, 2018 06:57 am ET
Aralez Announces First Quarter 2018 Financial Results
-1Q 2018 Net Revenues Increased to $38.1 Million Versus $26.0 Million in 1Q 2017-
May 08, 2018 06:57 am ET
Aralez Announces First Quarter 2018 Financial Results
-1Q 2018 Net Revenues Increased to $38.1 Million Versus $26.0 Million in 1Q 2017-
May 08, 2018 06:55 am ET
Aralez Announces New Strategic Direction
-Focus on Canadian Operations, supported by Toprol-XL® Franchise Revenues and Vimovo® Royalties-
May 08, 2018 06:55 am ET
Aralez Announces New Strategic Direction
-Focus on Canadian Operations, supported by Toprol-XL® Franchise Revenues and Vimovo® Royalties-
Apr 27, 2018 07:00 am ET
Aralez To Announce First Quarter 2018 Results On May 8, 2018
-Executive Management to Host Conference Call on May 8, 2018 at 8:00 a.m. ET-
Apr 27, 2018 07:00 am ET
Aralez To Announce First Quarter 2018 Results On May 8, 2018
-Executive Management to Host Conference Call on May 8, 2018 at 8:00 a.m. ET-
Mar 13, 2018 07:00 am ET
Aralez Announces Fourth Quarter and Full-Year 2017 Financial Results
-4Q 2017 Net Revenues Increased to $28.0 Million Versus $20.0 Million in the 4Q 2016-
Mar 13, 2018 07:00 am ET
Aralez Announces Fourth Quarter and Full-Year 2017 Financial Results
-4Q 2017 Net Revenues Increased to $28.0 Million Versus $20.0 Million in the 4Q 2016-
Mar 06, 2018 06:00 am ET
Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018
-Executive Management to Host Conference Call on March 13, 2018 at 8:30 a.m. ET-
Mar 06, 2018 06:00 am ET
Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018
-Executive Management to Host Conference Call on March 13, 2018 at 8:30 a.m. ET-
Jan 30, 2018 06:00 am ET
Aralez to Present at the 2018 BIO CEO and Investor Conference
MISSISSAUGA, Ontario, Jan. 30, 2018 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the executive management will participate in the 2018 BIO CEO and Investor Conference to be held February 12-13, 2018 in New York. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 11:00 a.m. local time on Tuesday, February 13, 2018.
Jan 30, 2018 06:00 am ET
Aralez to Present at the 2018 BIO CEO and Investor Conference
MISSISSAUGA, Ontario, Jan. 30, 2018 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the executive management will participate in the 2018 BIO CEO and Investor Conference to be held February 12-13, 2018 in New York. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 11:00 a.m. local time on Tuesday, February 13, 2018.
Nov 30, 2017 04:00 pm ET
Aralez Announces Departure of Chief Financial Officer
MISSISSAUGA, Ontario, Nov. 30, 2017 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced that Scott J. Charles, Chief Financial Officer, is leaving the Company to pursue other opportunities, effective immediately. Michael Kaseta will assume the position of Interim Chief Financial Officer ("CFO") along with his current duties as Corporate Controller. Mr. Kaseta has served as Corporate Controller since 2016 and brings a breadth of experience in all aspects of the Company's financial operations. Prior to joining Aralez, Mr. Kaseta served as
Nov 30, 2017 04:00 pm ET
Aralez Announces Departure of Chief Financial Officer
MISSISSAUGA, Ontario, Nov. 30, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced that Scott J. Charles, Chief Financial Officer, is leaving the Company to pursue other opportunities, effective immediately. Michael Kaseta will assume the position of Interim Chief Financial Officer ("CFO") along with his current duties as Corporate Controller. Mr. Kaseta has served as Corporate Controller since 2016 and brings a breadth of experience in all aspects of the Company's financial operations. Prior to joining Aralez, Mr. Kaseta ser
Nov 09, 2017 07:00 am ET
Aralez Announces Third Quarter 2017 Financial Results And Achieves Profitability on an Adjusted EBITDA Basis for the First Time in the Third Quarter
-3Q 2017 Net Revenues of $24.3 Million; Year-to-Date 2017 Net Revenues of $77.9 Million-
Nov 09, 2017 07:00 am ET
Aralez Announces Third Quarter 2017 Financial Results And Achieves Profitability on an Adjusted EBITDA Basis for the First Time in the Third Quarter
-3Q 2017 Net Revenues of $24.3 Million; Year-to-Date 2017 Net Revenues of $77.9 Million-
Oct 25, 2017 08:00 am ET
Aralez To Report Third Quarter 2017 Financial Results On November 9, 2017
-Executive Management to Host Conference Call on November 9, 2017 at 8:30 a.m. ET-
Oct 25, 2017 08:00 am ET
Aralez To Report Third Quarter 2017 Financial Results On November 9, 2017
-Executive Management to Host Conference Call on November 9, 2017 at 8:30 a.m. ET-
Aug 09, 2017 08:00 am ET
Aralez Reports Second Quarter 2017 Financial Results
MISSISSAUGA, Ontario, Aug. 9, 2017 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced financial results for the second quarter and first half of 2017. The Company also highlighted certain corporate and commercial updates. All figures are in U.S. dollars.
Aug 09, 2017 08:00 am ET
Aralez Reports Second Quarter 2017 Financial Results
MISSISSAUGA, Ontario, Aug. 9, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced financial results for the second quarter and first half of 2017. The Company also highlighted certain corporate and commercial updates. All figures are in U.S. dollars.
Jul 24, 2017 08:00 am ET
Aralez To Report Second Quarter 2017 Financial Results On August 9, 2017
-Executive Management to Host Conference Call on August 9, 2017 at 9:00 a.m. ET-
Jul 24, 2017 08:00 am ET
Aralez To Report Second Quarter 2017 Financial Results On August 9, 2017
-Executive Management to Host Conference Call on August 9, 2017 at 9:00 a.m. ET-
Jun 27, 2017 08:00 am ET
Aralez Announces District Court Decision to Uphold VIMOVO (Naproxen/Esomeprazole Magnesium) Patents
-Patents Covering VIMOVO Infringed by Proposed Generics Developed by Dr. Reddy's Laboratories, Mylan, and Lupin-
Jun 27, 2017 08:00 am ET
Aralez Announces District Court Decision to Uphold VIMOVO (Naproxen/Esomeprazole Magnesium) Patents
-Patents Covering VIMOVO Infringed by Proposed Generics Developed by Dr. Reddy's Laboratories, Mylan, and Lupin-
Jun 07, 2017 07:30 am ET
Aralez Announces National U.S. Commercial Launch Of Zontivity
-Zontivity® is the Only Approved Protease-Activated Receptor-1 (PAR-1) Inhibitor, a Receptor for Thrombin on the Platelet Considered to be a Potent Platelet Activator-
Jun 07, 2017 07:30 am ET
Aralez Announces National U.S. Commercial Launch Of Zontivity
-Zontivity® is the Only Approved Protease-Activated Receptor-1 (PAR-1) Inhibitor, a Receptor for Thrombin on the Platelet Considered to be a Potent Platelet Activator-
Jun 07, 2017 07:00 am ET
Aralez Announces Board Member Resignation
MISSISSAUGA, Ontario, June 7, 2017 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (the "Company") today announced it received a written letter of resignation from Jason M. Aryeh stating that he resigned, effective immediately, from his position on the Board of Directors of the Company. Mr. Aryeh did not resign as a result of any current dispute or disagreement with the Company. Mr. Aryeh was a valued member of the Board during the period he served as a director.
May 23, 2017 08:00 am ET
Aralez to present at the Jefferies Healthcare Conference
MISSISSAUGA, Ontario, May 23, 2017 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the executive management will participate in the Jefferies Healthcare Conference to be held June 6-9, 2017 in New York. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 8:30 a.m. local time on Wednesday, June 7, 2017.
May 23, 2017 08:00 am ET
Aralez to present at the Jefferies Healthcare Conference
MISSISSAUGA, Ontario, May 23, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the executive management will participate in the Jefferies Healthcare Conference to be held June 6-9, 2017 in New York. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 8:30 a.m. local time on Wednesday, June 7, 2017.
May 09, 2017 08:00 am ET
Aralez Reports First Quarter 2017 Financial Results
-First Quarter 2017 Net Revenues of $26.0 Million-
May 09, 2017 08:00 am ET
Aralez Reports First Quarter 2017 Financial Results
-First Quarter 2017 Net Revenues of $26.0 Million-
May 03, 2017 06:20 pm ET
Aralez Announces Voting Results From 2017 Annual And Special Meeting Of Shareholders
MISSISSAUGA, Ontario, May 3, 2017 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced the results of the matters voted upon at the Company's 2017 annual and special meeting (the "Meeting") of the shareholders of the Company (the "Shareholders") held earlier today, which included the election of directors, as described below.
May 03, 2017 06:20 pm ET
Aralez Announces Voting Results From 2017 Annual And Special Meeting Of Shareholders
MISSISSAUGA, Ontario, May 3, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced the results of the matters voted upon at the Company's 2017 annual and special meeting (the "Meeting") of the shareholders of the Company (the "Shareholders") held earlier today, which included the election of directors, as described below.
Apr 25, 2017 08:00 am ET
Aralez To Report First Quarter 2017 Financial Results On May 9, 2017
-Executive Management to Host Conference Call on May 9, 2017 at 9:00 a.m. ET-
Apr 25, 2017 08:00 am ET
Aralez To Report First Quarter 2017 Financial Results On May 9, 2017
-Executive Management to Host Conference Call on May 9, 2017 at 9:00 a.m. ET-
Apr 05, 2017 07:30 am ET
Aralez Announces Reduction In U.S. Sales Force And Cost Savings Program
-32% Reduction in the U.S. Sales Force-
Apr 05, 2017 07:30 am ET
Aralez Announces Reduction In U.S. Sales Force And Cost Savings Program
-32% Reduction in the U.S. Sales Force-
Mar 20, 2017 07:30 am ET
Aralez CEO Purchases 500,000 Shares Of Company Common Stock On Open Market
MISSISSAUGA, Ontario, March 20, 2017 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced that Adrian Adams, the Chief Executive Officer of the Company, acquired an additional 500,000 shares of the Company's common stock on March 15, 2017 in open-market purchases.
Mar 20, 2017 07:30 am ET
Aralez CEO Purchases 500,000 Shares Of Company Common Stock On Open Market
MISSISSAUGA, Ontario, March 20, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced that Adrian Adams, the Chief Executive Officer of the Company, acquired an additional 500,000 shares of the Company's common stock on March 15, 2017 in open-market purchases.
Mar 13, 2017 07:30 am ET
Aralez Reports Fourth Quarter And Full-Year 2016 Financial Results
-4Q16 Net Revenues Increased to $20 Million Versus $6 Million in the Comparable Period of 2015-
Mar 13, 2017 07:30 am ET
Aralez Reports Fourth Quarter And Full-Year 2016 Financial Results
-4Q16 Net Revenues Increased to $20 Million Versus $6 Million in the Comparable Period of 2015-
Feb 27, 2017 06:30 am ET
Aralez To Announce Fourth Quarter And Full-Year 2016 Results On March 13, 2017
-Executive Management to Host Conference Call on March 13, 2017 at 9:00 a.m. ET-
Feb 27, 2017 06:30 am ET
Aralez To Announce Fourth Quarter And Full-Year 2016 Results On March 13, 2017
-Executive Management to Host Conference Call on March 13, 2017 at 9:00 a.m. ET-
Feb 16, 2017 02:00 pm ET
Aralez to Present at the RBC Capital Markets Global Healthcare Conference
MISSISSAUGA, Ontario, Feb. 16, 2017 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that executive management will participate in the RBC Capital Markets Global Healthcare Conference to be held February 22-23, 2017. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 1:35 p.m. local time on Wednesday, February 22, 2017.
Feb 16, 2017 02:00 pm ET
Aralez to Present at the RBC Capital Markets Global Healthcare Conference
MISSISSAUGA, Ontario, Feb. 16, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that executive management will participate in the RBC Capital Markets Global Healthcare Conference to be held February 22-23, 2017. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 1:35 p.m. local time on Wednesday, February 22, 2017.
Feb 13, 2017 06:30 am ET
Aralez To Ring Closing Bell At Nasdaq On February 14, 2017
MISSISSAUGA, Ontario, Feb. 13, 2017 /CNW/ -- Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the Company will ring the Nasdaq Closing Bell at the Nasdaq MarketSite in Times Square, New York at 4:00 p.m. ET on Tuesday, February 14, 2017 to celebrate its commitment to cardiovascular disease and the commercial launch of Yosprala®.
Feb 13, 2017 06:30 am ET
Aralez To Ring Closing Bell At Nasdaq On February 14, 2017
MISSISSAUGA, Ontario, Feb. 13, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the Company will ring the Nasdaq Closing Bell at the Nasdaq MarketSite in Times Square, New York at 4:00 p.m. ET on Tuesday, February 14, 2017 to celebrate its commitment to cardiovascular disease and the commercial launch of Yosprala®.
Jan 11, 2017 06:00 am ET
Aralez Announces Issuance Of Additional U.S. Patent For Yosprala
MISSISSAUGA, Ontario, Jan. 11, 2017 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent entitled "Compositions and Methods for Delivery of Omeprazole Plus Acetylsalicylic Acid" that covers Yosprala™ (aspirin and omeprazole), the only prescription fixed-dose combination of an anti-platelet agent, aspirin, and the proton pump inhibitor, omeprazole, in the U.S.
Jan 11, 2017 06:00 am ET
Aralez Announces Issuance Of Additional U.S. Patent For Yosprala
MISSISSAUGA, Ontario, Jan. 11, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent entitled "Compositions and Methods for Delivery of Omeprazole Plus Acetylsalicylic Acid" that covers Yosprala™ (aspirin and omeprazole), the only prescription fixed-dose combination of an anti-platelet agent, aspirin, and the proton pump inhibitor, omeprazole, in the U.S.
Jan 09, 2017 06:15 am ET
Aralez Submits Marketing Authorization Application To The European Medicines Agency For PA10040
MISSISSAUGA, Ontario, Jan. 9, 2017 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational candidate, PA10040, for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.
Jan 09, 2017 06:15 am ET
Aralez Submits Marketing Authorization Application To The European Medicines Agency For PA10040
MISSISSAUGA, Ontario, Jan. 9, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational candidate, PA10040, for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.
Jan 09, 2017 06:00 am ET
Aralez Provides Update On PBM Formulary Status For Yosprala
-Secures Formulary Status with Express Scripts Inc. for Yosprala™-
Jan 09, 2017 06:00 am ET
Aralez Provides Update On PBM Formulary Status For Yosprala
-Secures Formulary Status with Express Scripts Inc. for Yosprala™-
Dec 19, 2016 11:00 am ET
Aralez Added To The NASDAQ Biotechnology Index
MISSISSAUGA, Ontario, Dec. 19, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced that it has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective as of the opening of trading on Monday, December 19, 2016.
Dec 19, 2016 11:00 am ET
Aralez Added To The NASDAQ Biotechnology Index
MISSISSAUGA, Ontario, Dec. 19, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced that it has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective as of the opening of trading on Monday, December 19, 2016.
Dec 19, 2016 06:30 am ET
Aralez Announces Commercial Launch Of BLEXTEN™ In Canada
MISSISSAUGA, Ontario, Dec. 19, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced the commercial launch of BLEXTEN™ (Bilastine 20 mg oral tablet) for the treatment of the symptoms of Seasonal Allergic Rhinitis (SAR) and Chronic Spontaneous Urticaria (CSU) (such as itchiness and hives) in Canada. BLEXTEN will be distributed in Canada by Tribute Pharmaceuticals Canada Inc. (Tribute), a subsidiary of the Company.
Dec 19, 2016 06:30 am ET
Aralez Announces Commercial Launch Of BLEXTEN™ In Canada
MISSISSAUGA, Ontario, Dec. 19, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced the commercial launch of BLEXTEN™ (Bilastine 20 mg oral tablet) for the treatment of the symptoms of Seasonal Allergic Rhinitis (SAR) and Chronic Spontaneous Urticaria (CSU) (such as itchiness and hives) in Canada. BLEXTEN will be distributed in Canada by Tribute Pharmaceuticals Canada Inc. (Tribute), a subsidiary of the Company.
Dec 15, 2016 06:30 am ET
Aralez Provides Update on PBM Formulary Status for Yosprala
-Secures Formulary Status with CVS Caremark for YOSPRALA™
Dec 15, 2016 06:30 am ET
Aralez Provides Update on PBM Formulary Status for Yosprala
-Secures Formulary Status with CVS Caremark for YOSPRALA™
Nov 30, 2016 07:00 am ET
Aralez to Participate at Two Upcoming Healthcare Conferences
MISSISSAUGA, Ontario, Nov. 30, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that Adrian Adams, Chief Executive Officer, will participate in the following healthcare conferences:
Nov 30, 2016 07:00 am ET
Aralez to Participate at Two Upcoming Healthcare Conferences
MISSISSAUGA, Ontario, Nov. 30, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that Adrian Adams, Chief Executive Officer, will participate in the following healthcare conferences:
Nov 14, 2016 07:00 am ET
New Post-Hoc Analysis Supports YOSPRALA™ Efficacy And Safety In Previous Heart Attack Patients Who Need Daily Aspirin Therapy To Prevent A Second Cardiovascular Event
-Shows Significant Reduction in Gastrointestinal Side Effects with Use of Fixed-Dose Combination of Aspirin and Proton Pump Inhibitor-
Nov 14, 2016 07:00 am ET
New Post-Hoc Analysis Supports YOSPRALA™ Efficacy And Safety In Previous Heart Attack Patients Who Need Daily Aspirin Therapy To Prevent A Second Cardiovascular Event
-Shows Significant Reduction in Gastrointestinal Side Effects with Use of Fixed-Dose Combination of Aspirin and Proton Pump Inhibitor-
Nov 07, 2016 07:15 am ET
Aralez Reports Third Quarter 2016 Financial Results
-Completed Acquisitions of ZONTIVITY®; Toprol-XL® and its Authorized Generic-
Nov 07, 2016 07:15 am ET
Aralez Reports Third Quarter 2016 Financial Results
-Completed Acquisitions of ZONTIVITY®; Toprol-XL® and its Authorized Generic-
Nov 02, 2016 08:30 am ET
Aralez to Present at the Jefferies London Healthcare Conference
MISSISSAUGA, Ontario, Nov. 2, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that executive management will participate in the Jefferies London Healthcare Conference to be held November 16-17, 2016. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 4:40 p.m. local time on Wednesday, November 16, 2016.
Nov 02, 2016 08:30 am ET
Aralez to Present at the Jefferies London Healthcare Conference
MISSISSAUGA, Ontario, Nov. 2, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that executive management will participate in the Jefferies London Healthcare Conference to be held November 16-17, 2016. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 4:40 p.m. local time on Wednesday, November 16, 2016.
Oct 31, 2016 10:40 am ET
Aralez Completes Acquisition Of Toprol-XL® And Its Authorized Generic From AstraZeneca
-Aralez Enters into Long-term Supply Agreement with AstraZeneca-
Oct 31, 2016 10:40 am ET
Aralez Completes Acquisition Of Toprol-XL® And Its Authorized Generic From AstraZeneca
-Aralez Enters into Long-term Supply Agreement with AstraZeneca-
Oct 24, 2016 07:30 am ET
Aralez To Announce Third Quarter 2016 Results On November 7, 2016
MISSISSAUGA, Ontario, Oct. 24, 2016 /CNW/ --Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that it will report its third quarter 2016 financial results on Monday, November 7, 2016, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 11:00 a.m. ET on such date to discuss the financial results and recent highlights.
Oct 24, 2016 07:30 am ET
Aralez To Announce Third Quarter 2016 Results On November 7, 2016
MISSISSAUGA, Ontario, Oct. 24, 2016 /PRNewswire/ --Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that it will report its third quarter 2016 financial results on Monday, November 7, 2016, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 11:00 a.m. ET on such date to discuss the financial results and recent highlights.
Oct 04, 2016 03:05 am ET
Aralez to Acquire From AstraZeneca U.S. Rights to Beta Blocker Toprol-XL®
-On an Adjusted EBITDA Basis, Transaction Expected to be EBITDA Accretive and to Move Profitability Forward to 2017-
Oct 04, 2016 03:05 am ET
Aralez to Acquire From AstraZeneca U.S. Rights to Beta Blocker Toprol-XL®
-On an Adjusted EBITDA Basis, Transaction Expected to be EBITDA Accretive and to Move Profitability Forward to 2017-
Oct 03, 2016 08:00 am ET
Aralez Announces U.S. Commercial Launch Of YOSPRALA For Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcers
MISSISSAUGA, Ontario, Oct. 3, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, announced today the availability of once-daily YOSPRALA™, the only prescription fixed-dose combination of aspirin, an anti-platelet agent, and omeprazole, a proton pump inhibitor (PPI), in the U.S. YOSPRALA is indicated for patients who require aspirin for secondary prevention of cardiovascular (CV) and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. YOSPRALA is being promoted by 110 sales representatives in
Oct 03, 2016 08:00 am ET
Aralez Announces U.S. Commercial Launch Of YOSPRALA For Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcers
MISSISSAUGA, Ontario, Oct. 3, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, announced today the availability of once-daily YOSPRALA™, the only prescription fixed-dose combination of aspirin, an anti-platelet agent, and omeprazole, a proton pump inhibitor (PPI), in the U.S. YOSPRALA is indicated for patients who require aspirin for secondary prevention of cardiovascular (CV) and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. YOSPRALA is being promoted by 110 sales representati
Sep 15, 2016 10:44 am ET
IIROC Trade Resumption - ARZ
TORONTO, Sept. 15, 2016 /CNW/ - Trading resumes in:
Sep 15, 2016 10:32 am ET
Aralez Announces FDA Approval Of YOSPRALA For Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcers
-Aralez Sales Force Will Be Expanded by 85 to 110 Sales Representatives by Launch-
Sep 15, 2016 10:32 am ET
Aralez Announces FDA Approval Of YOSPRALA For Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcers
-Aralez Sales Force Will Be Expanded by 85 to 110 Sales Representatives by Launch-
Sep 15, 2016 08:37 am ET
IIROC Trading Halt - ARZ
TORONTO, Sept. 15, 2016 /CNW/ - The following issues have been halted by IIROC:
Sep 07, 2016 09:53 am ET
IIROC Trade Resumption - ARZ
TORONTO, Sept. 7, 2016 /CNW/ - Trading resumes in:
Sep 07, 2016 09:37 am ET
IIROC Trading Halt - ARZ
TORONTO, Sept. 7, 2016 /CNW/ - The following issues have been halted by IIROC:
Sep 07, 2016 09:34 am ET
Aralez Acquires United States And Canadian Rights To ZONTIVITY From Merck
-Acquired ZONTIVITY® in the U.S. and Canada-
Sep 07, 2016 09:34 am ET
Aralez Acquires United States And Canadian Rights To ZONTIVITY From Merck
-Acquired ZONTIVITY® in the U.S. and Canada-
Aug 09, 2016 09:00 am ET
Aralez Reports Second Quarter 2016 Financial Results
MISSISSAUGA, Ontario, Aug. 9, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced financial results for the second quarter ended June 30, 2016. The Company also highlighted certain corporate, commercial, and regulatory updates. All figures are in U.S. dollars.
Aug 09, 2016 09:00 am ET
Aralez Reports Second Quarter 2016 Financial Results
MISSISSAUGA, Ontario, Aug. 9, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced financial results for the second quarter ended June 30, 2016. The Company also highlighted certain corporate, commercial, and regulatory updates. All figures are in U.S. dollars.
Jul 06, 2016 09:00 am ET
Aralez To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
MISSISSAUGA, Ontario, July 6, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that executive management will participate in the Cantor Fitzgerald 2nd Annual Healthcare Conference to be held July 12-13, 2016 in New York. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 4:00 p.m. local time on Wednesday, July 13, 2016.
Jul 06, 2016 09:00 am ET
Aralez To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
MISSISSAUGA, Ontario, July 6, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that executive management will participate in the Cantor Fitzgerald 2nd Annual Healthcare Conference to be held July 12-13, 2016 in New York. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 4:00 p.m. local time on Wednesday, July 13, 2016.
Jun 16, 2016 10:07 pm ET
Aralez Announces Voting Results From 2016 Annual General Meeting Of Shareholders
MISSISSAUGA, Ontario, June 16, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), today announced the results of the matters voted upon at the Company's 2016 annual general meeting (the "Meeting") of shareholders (the "Shareholders") held earlier today, which included the election of directors, as described below.
Jun 16, 2016 10:07 pm ET
Aralez Announces Voting Results From 2016 Annual General Meeting Of Shareholders
MISSISSAUGA, Ontario, June 16, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), today announced the results of the matters voted upon at the Company's 2016 annual general meeting (the "Meeting") of shareholders (the "Shareholders") held earlier today, which included the election of directors, as described below.
Jun 02, 2016 08:00 am ET
Jun 02, 2016 08:00 am ET
Jun 01, 2016 07:00 am ET
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen/esomeprazole) Delayed Release Tablets
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced the issuance of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/980,639, entitled "Method for Delivering a Pharmaceutical Composition to Patient in Need Thereof" that covers the U.S. approved medicine VIMOVO® (naproxen/esomeprazole) delayed release tablets.
May 16, 2016 08:30 am ET
Aralez Distributes Meeting Materials For 2016 Annual General Meeting Of Shareholders
MILTON, Ontario, May 16, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), today announced that it has distributed its proxy statement and related meeting materials ("Meeting Materials") in connection with its upcoming 2016 Annual General Meeting of Shareholders (the "Annual Meeting") to be held on Thursday, June 16, 2016 at 1:00 p.m. ET at the offices of Stikeman Elliott LLP, 5300 Commerce Court West, 199 Bay Street, Toronto, ON, Canada M5L 1B9. The Meeting Materials are available on the Company's website at www.aralez.com, on EDGAR at www.sec.
May 16, 2016 08:30 am ET
Aralez Distributes Meeting Materials For 2016 Annual General Meeting Of Shareholders
MILTON, Ontario, May 16, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), today announced that it has distributed its proxy statement and related meeting materials ("Meeting Materials") in connection with its upcoming 2016 Annual General Meeting of Shareholders (the "Annual Meeting") to be held on Thursday, June 16, 2016 at 1:00 p.m. ET at the offices of Stikeman Elliott LLP, 5300 Commerce Court West, 199 Bay Street, Toronto, ON, Canada M5L 1B9. The Meeting Materials are available on the Company's website at www.aralez.com, on EDGAR at w
May 10, 2016 08:00 am ET
Aralez Reports First Quarter 2016 Financial Results
-First Quarter 2016 Includes the Operations of Tribute from February 5, 2016 through March 31, 2016-
May 10, 2016 08:00 am ET
Aralez Reports First Quarter 2016 Financial Results
-First Quarter 2016 Includes the Operations of Tribute from February 5, 2016 through March 31, 2016-
Apr 28, 2016 08:05 am ET
Aralez To Present At The Deutsche Bank 41st Annual Healthcare Conference
MILTON, Ontario, April 28, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that its executive management will participate in the Deutsche Bank 41st Annual Healthcare Conference to be held May 4-5, 2016 in Boston. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 1:30 p.m. local time on Thursday, May 5, 2016.
Apr 28, 2016 08:05 am ET
Aralez To Present At The Deutsche Bank 41st Annual Healthcare Conference
MILTON, Ontario, April 28, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that its executive management will participate in the Deutsche Bank 41st Annual Healthcare Conference to be held May 4-5, 2016 in Boston. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 1:30 p.m. local time on Thursday, May 5, 2016.
Apr 28, 2016 08:00 am ET
Aralez To Announce First Quarter 2016 Results On May 10, 2016
-Executive Management to Host Conference Call on May 10, 2016 at 8:30 a.m. ET-
Apr 28, 2016 08:00 am ET
Aralez To Announce First Quarter 2016 Results On May 10, 2016
-Executive Management to Host Conference Call on May 10, 2016 at 8:30 a.m. ET-
Apr 25, 2016 08:15 am ET
Aralez To Present At The Bloom Burton & Co. Healthcare Investor Conference
MILTON, Ontario, April 25, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that its executive management will participate in the Bloom Burton & Co. Healthcare Investor Conference to be held May 2-3, 2016 in Toronto. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 11:30 a.m. local time on Monday, May 2, 2016.
Apr 25, 2016 08:15 am ET
Aralez To Present At The Bloom Burton & Co. Healthcare Investor Conference
MILTON, Ontario, April 25, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that its executive management will participate in the Bloom Burton & Co. Healthcare Investor Conference to be held May 2-3, 2016 in Toronto. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 11:30 a.m. local time on Monday, May 2, 2016.
Apr 25, 2016 08:00 am ET
Aralez Receives Health Canada Approval For BLEXTEN™
MILTON, Ontario, April 25, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced the Health Canada approval of BLEXTEN™ (bilastine 20 mg oral tablet) for the treatment of the symptoms of Seasonal Allergic Rhinitis (SAR) and Chronic Spontaneous Urticaria (CSU) (such as itchiness and hives). The approval was granted to Aralez Pharmaceuticals Trading DAC, a subsidiary of Aralez formed under the laws of Ireland. BLEXTEN will be distributed in Canada by Tribute Pharmaceuticals Canada Inc., also
Apr 25, 2016 08:00 am ET
Aralez Receives Health Canada Approval For BLEXTEN™
MILTON, Ontario, April 25, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced the Health Canada approval of BLEXTEN™ (bilastine 20 mg oral tablet) for the treatment of the symptoms of Seasonal Allergic Rhinitis (SAR) and Chronic Spontaneous Urticaria (CSU) (such as itchiness and hives). The approval was granted to Aralez Pharmaceuticals Trading DAC, a subsidiary of Aralez formed under the laws of Ireland. BLEXTEN will be distributed in Canada by Tribute Pharmaceuticals Canada Inc.
Apr 20, 2016 08:00 am ET
Aralez Announces Several Corporate Updates
MILTON, Ontario, April 20, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced several corporate updates.
Apr 20, 2016 08:00 am ET
Aralez Announces Several Corporate Updates
MILTON, Ontario, April 20, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced several corporate updates.
Apr 19, 2016 05:15 pm ET
Aralez Appoints James L. Hall As General Manager Of Canadian Business
MILTON, Ontario, April 19, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced that James L. Hall will be appointed to General Manager of its wholly owned subsidiary, Tribute Pharmaceuticals Canada Inc., effective May 16, 2016.
Apr 19, 2016 05:15 pm ET
Aralez Appoints James L. Hall As General Manager Of Canadian Business
MILTON, Ontario, April 19, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced that James L. Hall will be appointed to General Manager of its wholly owned subsidiary, Tribute Pharmaceuticals Canada Inc., effective May 16, 2016.
Apr 04, 2016 08:00 am ET
Aralez to open Toronto stock exchange on April 5, 2016
MILTON, Ontario, April 4, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that the Company will open the Toronto Stock Exchange at 9:00 a.m. ET on Tuesday, April 5, 2016.
Apr 04, 2016 08:00 am ET
Aralez to open Toronto stock exchange on April 5, 2016
MILTON, Ontario, April 4, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that the Company will open the Toronto Stock Exchange at 9:00 a.m. ET on Tuesday, April 5, 2016.
Mar 28, 2016 08:00 am ET
Aralez Announces FDA Acceptance of New Drug Application for YOSPRALA™
MILTON, Ontario, March 28, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has acknowledged acceptance of the New Drug Application ("NDA") for its investigational candidate, YOSPRALA™ (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. The FDA Prescription Drug User Fee Act ("PDUFA") goal date for a decision is September 14, 2016.
Mar 28, 2016 08:00 am ET
Aralez Announces FDA Acceptance of New Drug Application for YOSPRALA™
MILTON, Ontario, March 28, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has acknowledged acceptance of the New Drug Application ("NDA") for its investigational candidate, YOSPRALA™ (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. The FDA Prescription Drug User Fee Act ("PDUFA") goal date for a decision is September 14, 2016.
Mar 15, 2016 08:00 am ET
Aralez Reports Fourth Quarter And Full-Year 2015 Results
- Announced Today the Resubmission to the FDA of the NDA for YOSPRALA™-
Mar 15, 2016 08:00 am ET
Aralez Reports Fourth Quarter And Full-Year 2015 Results
- Announced Today the Resubmission to the FDA of the NDA for YOSPRALA™-
Mar 15, 2016 07:30 am ET
Aralez resubmits to FDA New Drug Application for YOSPRALA
MILTON, Ontario, March 15, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced that it has resubmitted to the U.S. Food and Drug Administration ("FDA") the New Drug Application ("NDA") for its investigational candidate, YOSPRALA™ (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.
Mar 15, 2016 07:30 am ET
Aralez resubmits to FDA New Drug Application for YOSPRALA
MILTON, Ontario, March 15, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced that it has resubmitted to the U.S. Food and Drug Administration ("FDA") the New Drug Application ("NDA") for its investigational candidate, YOSPRALA™ (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.
Mar 14, 2016 07:00 am ET
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen/esomeprazole) Delayed Release Tablets
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced the issuance of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/954,082, entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" that covers the U.S. approved medicine VIMOVO® (naproxen/esomeprazole) delayed release tablets.
Mar 01, 2016 07:00 am ET
Aralez To Announce Fourth Quarter And Full-Year 2015 Results On March 15, 2016
-Executive Management to Host Conference Call on March 15, 2016 at 8:30 a.m. ET-
Mar 01, 2016 07:00 am ET
Aralez To Announce Fourth Quarter And Full-Year 2015 Results On March 15, 2016
-Executive Management to Host Conference Call on March 15, 2016 at 8:30 a.m. ET-
Feb 22, 2016 07:00 am ET
Aralez To Present At The Cowen and Company 36th Annual Healthcare Conference
MILTON, Ontario, Feb. 22, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that members of its executive management will participate in the Cowen and Company 36th Annual Healthcare Conference to be held March 7-9, 2016 in Boston. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 1:20 p.m. local time on Monday, March 7, 2016.
Feb 22, 2016 07:00 am ET
Aralez To Present At The Cowen and Company 36th Annual Healthcare Conference
MILTON, Ontario, Feb. 22, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that members of its executive management will participate in the Cowen and Company 36th Annual Healthcare Conference to be held March 7-9, 2016 in Boston. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 1:20 p.m. local time on Monday, March 7, 2016.
Feb 12, 2016 07:00 am ET
Aralez to Ring Closing Bell at Nasdaq on February 16, 2016
MILTON, Ontario, Feb. 12, 2016 /CNW/ -- Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the Company will ring the Nasdaq Closing Bell at the Nasdaq MarketSite in Times Square, New York at 4:00 p.m. ET on Tuesday, February 16, 2016 to celebrate the formation of Aralez.
Feb 12, 2016 07:00 am ET
Aralez to Ring Closing Bell at Nasdaq on February 16, 2016
MILTON, Ontario, Feb. 12, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the Company will ring the Nasdaq Closing Bell at the Nasdaq MarketSite in Times Square, New York at 4:00 p.m. ET on Tuesday, February 16, 2016 to celebrate the formation of Aralez.
Feb 05, 2016 01:17 pm ET
POZEN And Tribute Combine To Create Aralez Pharmaceuticals Inc.
-Transformative Transaction Creates Premier Specialty Pharma Company with a Broad Product Portfolio-
Feb 05, 2016 01:17 pm ET
POZEN And Tribute Combine To Create Aralez Pharmaceuticals Inc.
-Transformative Transaction Creates Premier Specialty Pharma Company with a Broad Product Portfolio-
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
